Final efficacy and safety data, and exploratory molecular profiling from the phase III ALUR study of alectinib versus chemotherapy in crizotinib-pretreated ALK-positive non-small-cell lung cancer

BACKGROUND: At the primary data cut-off, the ALUR study demonstrated significantly improved progression-free survival (PFS) and central nervous system (CNS) objective response rate (ORR) with alectinib versus chemotherapy in pretreated, advanced anaplastic lymphoma kinase (ALK)-positive non-small-ce...

Descripción completa

Detalles Bibliográficos
Autores principales: Wolf, J., Helland, Å., Oh, I.-J., Migliorino, M.R., Dziadziuszko, R., Wrona, A., de Castro, J., Mazieres, J., Griesinger, F., Chlistalla, M., Cardona, A., Ruf, T., Trunzer, K., Smoljanovic, V., Novello, S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8777286/
https://www.ncbi.nlm.nih.gov/pubmed/35042152
http://dx.doi.org/10.1016/j.esmoop.2021.100333

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8777286/
https://www.ncbi.nlm.nih.gov/pubmed/35042152
http://dx.doi.org/10.1016/j.esmoop.2021.100333

Ejemplares similares